Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to 207.99%.

  • Regenxbio's EBITDA Margin rose 313500.0% to 207.99% in Q3 2025 from the same period last year, while for Sep 2025 it was 110.33%, marking a year-over-year increase of 1647600.0%. This contributed to the annual value of 268.11% for FY2024, which is 117100.0% up from last year.
  • Latest data reveals that Regenxbio reported EBITDA Margin of 207.99% as of Q3 2025, which was up 313500.0% from 331.75% recorded in Q2 2025.
  • Regenxbio's 5-year EBITDA Margin high stood at 73.43% for Q4 2021, and its period low was 397.71% during Q1 2024.
  • Over the past 5 years, Regenxbio's median EBITDA Margin value was 242.03% (recorded in 2024), while the average stood at 238.68%.
  • Per our database at Business Quant, Regenxbio's EBITDA Margin crashed by -2555300bps in 2022 and then surged by 4045200bps in 2025.
  • Regenxbio's EBITDA Margin (Quarter) stood at 73.43% in 2021, then plummeted by -348bps to 182.1% in 2022, then crashed by -48bps to 269.68% in 2023, then grew by 10bps to 242.03% in 2024, then grew by 14bps to 207.99% in 2025.
  • Its last three reported values are 207.99% in Q3 2025, 331.75% for Q2 2025, and 6.81% during Q1 2025.